SH3GL1 and glioma: When the antibody levels were divided into 2 groups with a cut-off value of 0.383 corresponding to the mean + 2 standard deviations (SD) of SH3GL1 antibodies in healthy volunteers, the positive rate of patients with low-grade glioma was 62.5% (25 of 40), whereas those of patients with high-grade glioma and healthy volunteers were 8.9% (5 of 56) and 15.6% (5 of 32), respectively.